Document:

<PAGE>
                                                                   EXHIBIT 10.50

                               LICENSE AGREEMENT

*** Confidential treatment has been requested as to certain portions of this
agreement. Such omitted confidential information has been filed separately with
the Securities and Exchange Commission pursuant to Rule 24b-2 under the
Securities Exchange Act of 1934, as amended, and the Commission's rules and
regulations promulgated under the Freedom of Information Act, pursuant to a
request of confidential treatment.

                  This License Agreement (this "Agreement") is made and entered
into as of June 8, 2000, by and between Senetek PLC, a British public limited
company with offices located at 620 Airpark Road, Napa, California 94558
("Senetek"), and Revlon Consumer Products Corporation, a Delaware corporation
with offices located at 625 Madison Avenue, New York, New York 10022, and its
direct and indirect subsidiaries ("Revlon").

                                   BACKGROUND

                  A. Senetek has developed and holds certain Patents (as defined
below) relating to the use as a skin care product of formulations containing
Kinetin.

                  B. Revlon desires to manufacture, market and sell in the Mass
Market (as defined below) specific formulations containing Kinetin and analogs
thereof, except Zeatin, for use as a skin care product.

                  C. Senetek is willing to grant Revlon the right to
manufacture, market and sell such formulations in such market all as set forth
in this Agreement.

                  D. Simultaneously with the execution of this Agreement,
Senetek is issuing to Revlon a warrant to purchase securities of Senetek.

                  Accordingly, in consideration of the mutual promises,
covenants, and conditions set forth below, the parties agree as follows:

1.       DEFINITIONS

                  When used in this Agreement, each of the following capitalized
terms shall have the respective meaning set forth in this Article.

     1.1 "Advertising and Promotional Expenses" means reasonable costs of
advertising, including media (including fees of Revlon's in-house advertising
agency (Tarlow Advertising) as actually recorded and reported at up to 15% of
media cost), point of purchase and other advertising and consumer spending,
merchandise displays, market research costs, including reasonable concept and
consumer testing costs, reasonable talent fees, reasonable direct mail costs,
reasonable couponing costs, free sample insert and magazine insert costs, costs
for the development and manufacture of non-revenue items such as trial sizes,
testers and samples, costs for public relations events and expenses, trade
related spending such as trade allowances, trade shows and in-store promotional
events, and selling expenses such as the cost of sell sheets and similar
materials.

     1.2 "Affiliate" means (a) any company beneficially owned or controlled to
the extent of at least fifty percent (50%) of its issued and voting or equity
capital securities by a party to this Agreement and any other company so owned
or controlled (directly or indirectly) by any such company or the owner of any
such company, or (b) any partnership, joint venture or other entity directly or
indirectly controlled by, controlling, or under common control of, to the extent
of fifty percent (50%) or more of voting power (or otherwise having power to
control its general

<PAGE>

activities) by a party to this Agreement, but in each case only for so long as
such ownership or control shall continue.

     1.3 "Agreement Date" means the date of this Agreement first set forth
above.

     1.4 "Best Efforts" shall mean that commercially reasonable degree of
effort, expertise, knowledge and resources which one skilled, able, familiar
with and experienced in the matters set forth herein would utilize and otherwise
apply with respect to fulfilling a like obligation subject to existing legal,
contractual and other restrictions.

     1.5 "Calendar Quarter" means a period beginning on the first day of
January, April, July or October and ending on the last day of March, June,
September, or December, respectively.

     1.6 "Color Cosmetics" means a product applied to the skin, hair or nails
primarily for purposes of decoration and not primarily for the amelioration of
the effects of aging.

     1.7 "Combination Products" means Products that include in addition to
Kinetin (i) an "active ingredient" in a formula that is either patent pending or
patented by Revlon or an Affiliate of Revlon or (ii) an "active ingredient" that
is licensed or purchased in exchange for material consideration from a party
other than Senetek, Revlon or an Affiliate of Revlon.

     1.8 "Contract Year" means a period beginning on any July 1 during the Term
and ending on the first to occur of the day before June 30 of the next year and
the termination of this Agreement; provided, however, that the first Contract
Year shall include the period between the date of this Agreement and June 30,
2002.

     1.9 "Disclosure Schedule" means Schedule 1.9.
                                     ------------

     1.10 "Documentation" means the documentation relating to the Patents and
Know-How identified in Schedule 1.10.
                       -------------

     1.11 "Final Adjudication" means any decision by a Governmental Entity of
competent jurisdiction if either (a) any and all appeals (including to other
Governmental Entities of competent jurisdiction) in connection with the
adjudication are exhausted or (b) the time for any such appeal shall have passed
without such appeal having been perfected.

     1.12 "Finished Form" means manufactured in accordance with the
Specifications.

     1.13 "Government Entity" means any competent governmental agency, board,
authority, commission, court or other governmental entity having lawful
jurisdiction.

     1.14 "Improvement" means any information, discovery, creation, derivative
work, invention, or trade secret, whether or not patented or patentable or
copyrighted or copyrightable, that relates to or is based upon the Patents or
Know-How and is developed or otherwise acquired by Senetek or its Affiliates to
the extent that such Improvement is not subject to an agreement or commitment
precluding Senetek from making it available to Revlon (i) in the case of
technology developed by Senetek or an Affiliate of Senetek, if such agreement or
commitment is in effect on

                                       2

<PAGE>

the date of this Agreement and disclosed in the Disclosure Schedule or (ii) in
the case of technology acquired other than from an Affiliate of Senetek, if such
agreement or commitment is in effect with respect to the technology before it is
acquired by Senetek or as a condition to acquisition by Senetek (it being
understood that Senetek will not act in bad faith to induce the creation of such
a restrictive provision in connection with the acquisition of such technology
and will use Best Efforts to eliminate any such restriction); provided, however,
that Improvements shall not include Zeatin or any information, discovery,
creation, derivative work, invention, or trade secret, whether or not patented
or patentable or copyrighted or copyrightable, to the extent the same relates
only to Zeatin.

     1.16 "Know-How" means such know-how, special knowledge, technical or other
information, whether or not patented or patentable, owned or controlled by
Senetek or its Affiliates at any time prior to or during the term of this
Agreement specifically related to the development, manufacture or use of the
Products to the extent that such know-how, special knowledge, technical or other
information is not subject to an agreement or commitment precluding Senetek from
making it available to Revlon (i) in the case of technology developed by Senetek
or an Affiliate of Senetek, if such agreement or commitment is in effect on the
date of this Agreement and disclosed in the Disclosure Schedule or (ii) in the
case of technology acquired other than from an Affiliate of Senetek, if such
agreement or commitment is in effect with respect to the technology before it is
acquired by Senetek or as a condition to acquisition by Senetek (it being
understood that Senetek will not act in bad faith to induce the creation of such
a restrictive provision in connection with the acquisition of such technology
and will use Best Efforts to eliminate any such restriction); provided, however,
that Know-How shall not include know-how, special knowledge, technical or other
information, whether or not patented or patentable, to the extent the same
relates only to Zeatin.

     1.17 "Market Channel" means the channel of trade set forth on Schedule 2.1.
                                                                  -------------

     1.18 "Net Sales" shall mean all amounts received by Revlon for Products
less (to the extent consistent with reasonable industry practices and shown on
customer invoices as separate items): the amount of discounts and allowances
granted by Revlon and taken by Revlon's customers in the trade and amounts
actually allowed or credited on returns. Net Sales shall not include any pass
through costs invoiced to customers as separate items for freight or shipping
insurance.

     1.19 "Minimum Sales Levels" means the amount of Net Sales identified on
Schedule 1.19 with respect to each Market Channel and each Contract Year.
-------------

     1.20 "Minimum Royalty" means those amounts set forth on Schedule 1.20.
                                                             -------------

     1.21 "Patents" means the patents for Kinetin set forth on Schedule 1.21.
                                                               -------------

     1.22 "Person" shall be broadly construed to include any governmental
entity, legal entity, or individual.

     1.23 "Products" means existing and improved formulations of cosmetic
products containing Kinetin for skin treatment, but excluding (i) any product
subject to regulation as a

                                       3

<PAGE>

prescription drug, (ii) any product with a concentration of Kinetin of 0.1% or
more, or (iii) any product containing Zeatin or analogues.

1.24 "Promotion Commitment" has the meaning set forth in Section 3.1.4.
                                                         -------------
1.25 "Revlon Brand" means the Products marketed by Revlon under Revlon's and its
Affiliates' trademarks or by Revlon's sub-licensees, under their trademarks.

1.26 "Revlon Confidential Information" means marketing, sales, financial,
scientific, and other non-public and/or proprietary information concerning the
products, projects, business and operations of Revlon disclosed by Revlon to
Senetek or of which Senetek gains knowledge during the Term.

1.27 "Revlon Products" means Products manufactured by any Person for or under
the direction of Revlon including by Revlon or any sub-licensee of Revlon.

1.28 "Senetek Confidential Information" means the Know-How, non-public
information concerning the Patents, Improvements, marketing, sales, financial,
scientific, and other non-public and/or proprietary information concerning the
products, projects, business and operations of Senetek, including the
manufacture, use, or sale of the Products, disclosed by Senetek to Revlon or of
which Revlon gains knowledge during the Term.

1.29 "Sub-Territories" means (i) North and South America, (ii) Asia and the
Middle East (excluding Japan), (iii) Japan, (iv) Europe, and (v) Africa, with
each enumerated area being an individual "Sub-Territory".

1.30 "Territory" means the geographic region(s) identified on Schedule 2.1.
                                                              ------------

1.31 "Term" means the period starting on the date of this Agreement and ending
(if not earlier terminated pursuant to the other terms of this Agreement) with
respect to the Territories located in the areas set forth in Column A of the
following table upon the expiration of the last to expire of the Patents
containing a Valid Claim covering the Products issued by the jurisdiction set
for in Column B of the following table:
<TABLE>
<CAPTION>

-------------------------------- ---------------------------------------
<S>                              <C>
Column A                         Column B
-------------------------------- ---------------------------------------
North America                    United States
-------------------------------- ---------------------------------------
Europe                           European Patent Office
-------------------------------- ---------------------------------------
South America                    Argentina
-------------------------------- ---------------------------------------
Asia                             People's Republic of China
-------------------------------- ---------------------------------------
</TABLE>
                                       4

<PAGE>

1.32 "Trial Size" means a Unit that is a sampling vehicle with a fill weight
that is less than the fill weight of regular business product and that is sold
or given to consumers free of charge, in either case, with the goal of
generating trial and awareness of Products.

1.33 "Unit" means an individual packaged unit of Product.

1.34 "Valid Claim" means any claim in an unexpired patent or patent application
included within the Patents that has not been disclaimed or held invalid or
unenforceable by a Governmental Entity of competent jurisdiction in a Final
Adjudication.

1.35 "Warrant" means the Warrant to purchase securities of Senetek issued to
Revlon on the same date as this Agreement.

2.       LICENSE

     2.1 Grant of License. Senetek hereby grants to Revlon during the Term a
license under the Patents to make, have made, use and sell the Products under
the Revlon Brand only into the Market Channel identified on Schedule 2.1 and
                                                            ------------
only within the Territory identified on Schedule 2.1 with respect to such Market
                                        ------------
Channel and to use the Patents, Know-How, Improvements and Documentation to
facilitate such manufacture and sale, in each case subject to terms of this
Agreement.

     2.2 Exclusivity. Senetek agrees that, for so long during the Term as Revlon
meets the Minimum Sales Levels and Promotion Commitment during each Contract
Year, Senetek and its Affiliates, will not make, have made up, or sell and will
not grant to any third party rights to make, use or sell Products in the Market
Channel in the respective Territory identified on Schedule 2.1 (the "Exclusivity
                                                  ------------
Right"). The Exclusivity Right may be terminated by Senetek with respect to a
Sub-Territory upon notice given to Revlon if Revlon fails to make a meaningful
launch of the product in the Sub-Territory by the end of the second Contract
Year. Nothing in this Agreement shall be construed to limit Senetek's use of
Know-How or Improvements in connection with Zeatin or to limit the sale of
Products by Senetek, its Affiliates, or licensees outside the Mass Market Market
Channel or in the Mass Market Channel outside of the Territory then granted to
Revlon under this Agreement.

     2.3 Right of First Offer. During the Term, for so long as the Exclusivity
Right is in effect, Revlon shall have the right of first offer to obtain the
right to make, have made and sell through the licensed Market Channel in the
Territory products utilizing Zeatin and other new Kinetin analogues as well as
new skin care technologies developed or acquired by Senetek with or from any
third party or Affiliate including without limitation the University of Aahrus,
Denmark; provided, however, that such right of first offer shall not apply with
regard to (i) any product subject to regulation as prescription drugs, (ii) any
product with a concentration of Kinetin of 0.1% or more or (iii) products that
are protected through patents or other rights as to, owned by, or vested in a
third party and as to which Senetek or its Affiliates have not acquired the
right to grant rights to Revlon after Best Efforts to obtain such rights. Revlon
shall have sixty (60) days from the date that Senetek notifies Revlon that such
a new or enhanced product is or may become available for sale to deliver an
offer to Senetek setting forth in reasonable detail the terms upon which Revlon
would manufacture and/or sell such product. If Senetek elects not

                                       5

<PAGE>

to accept Revlon's offer (or if no offer is made within such period), Senetek
shall be free to grant such rights to others on terms no better to such other
party than those last offered by Revlon (provided that Senetek certifies the
same to Revlon upon the request of Revlon), exercise such rights itself, or any
combination thereof, all in Senetek's sole and absolute discretion.

     2.4 Royalty. On sales by Revlon of any Products, a royalty shall be due to
Senetek calculated at the rate "*Filed Separately with the Commission*" of Net
Sales for all Products except for (x) Trial Sizes, for which the rate shall be
"*Filed Separately with the Commission*"of Net Sales and (y) Color Cosmetics and
Combination Products, for which the rate shall be "*Filed Separately with the
Commission*"of Net Sales. Such royalties shall be paid with respect to each
Calendar Quarter within 30 days after the end of such Calendar Quarter.
Royalties due upon the sale of any Products by any permitted sub-licensee of
Revlon shall be calculated based upon the Net Sales of such sub-licensee. All
royalty payments shall be accompanied by a reasonably detailed accounting
setting forth the basis upon which such payment was calculated ("Royalty
Report"). Royalties due shall not be subject to any offset for any claim Revlon
may have against Senetek unless and until such claim is approved by Senetek in
writing or determined to be valid in a Final Adjudication pursuant to the
dispute resolution procedures set forth in this Agreement.

     2.5 License Fee. Upon the execution of this Agreement, Revlon shall pay
Senetek "*Filed Separately with the Commission*" (the "License Fee"). The
License Fee is non-refundable.

     2.6 No Other Rights. It is expressly understood that this Agreement grants
no rights to Revlon except those express rights set forth in this Article 2.
Without limiting the foregoing, it is understood and agreed that Revlon has no
right pursuant to this Agreement to, and shall not, (i) sell or knowingly permit
its customers to sell any Product other than into the Market Channels within the
Territory to the extent legally permissible to prohibit or restrict such
activity applicable to such Market Channel, (ii) sell Products under any brand
or with labeling other than the Revlon Brand or (iii) make, have made, use or
sell products containing Kinetin for skin treatment that are not Products. Upon
any termination of this Agreement, Revlon shall have no right of any kind with
respect to the Products, Patents, Know How or Improvements other than the right
to complete the sale within six months of such termination of Products then
lawfully in its possession. Nothing in the foregoing sentence shall diminish
Revlon's rights in any trademark or other intellectual property owned by Revlon
and used in connection with the Products. It is expressly understood that all
formulas developed by Revlon for Products pursuant to this Agreement shall
remain the sole property of Revlon; provided, however, that nothing in this
agreement shall be construed to restrict Senetek's use of Improvements,
Know-How, Documentation or other technology developed by or for it other than in
the Market Channel in the Territory. Revlon will be permitted to file, prosecute
and maintain worldwide patent rights on such formulas in its own name, provided
however, that in no event will any patents or patent application contain claims
that would restrict Senetek or any Revlon or assignee of Senetek, from making,
using, or selling any Kinetin or Kinetin analogues covered by the Patents.

     2.8 Packaging. All Product packaging shall, to the extent that available
Product packaging space can reasonably accommodate same, include the following
or a similar, statement presented in a manner consistent with industry practice:
"Licensed from Senetek. Pat.

                                       6

<PAGE>

Nos. 5,371,089, 5,602,139 & others." or "Sold under license from Senetek PLC.
Pat. Nos. 5,371,089, 5,602,139 & others."

3. REPRESENTATIONS, WARRANTIES AND CERTAIN COVENANTS OF THE PARTIES

     3.1 Representations, Warranties and Covenants of Revlon. Revlon represents,
warrants and covenants as follows:

     3.1.1 Qualifications and Authorization. Revlon is a corporation duly
formed, validly existing and in good standing in the state of Delaware with full
corporate power and authority to conduct its business as it is now conducted and
to enter into and perform this Agreement. Revlon is duly licensed or qualified
to do business and is in good standing in each jurisdiction in which its
operations or ownership of assets in connection with this Agreement requires
such licensing or qualification.

     3.1.2 No Conflict or Violation. Neither the execution, delivery or
performance of this Agreement, nor compliance by Revlon with any of the
provisions hereof, will (i) violate or conflict with any provision of the
Certificate of Incorporation or Bylaws of Revlon, (ii) violate, conflict with,
or result in a breach of any provision of, or constitute a default (or an event
which, with notice or lapse of time or both, would constitute a default) under,
or result in the creation of any encumbrance upon any of Revlon's assets under,
any of the terms, conditions or provisions of any material contract,
indebtedness, note, bond, indenture, security or pledge agreement, commitment,
license, lease, franchise, permit, agreement, or other instrument or obligation
to which Revlon is a party, or (iii) violate any statute, rule, regulation,
ordinance, code, order, judgment, ruling, writ, injunction, decree or award
applicable to Revlon, except, in the case of each of clauses (i), (ii) and (iii)
above, for such violations, conflicts, breaches, defaults or creations of
encumbrances which, in the aggregate, would not have a material adverse affect
on the business of Revlon or its ability to perform this Agreement.

     3.1.3 Compliance With Laws. Revlon shall comply in all material respects
with any law, regulation, ordinance, order, injunction, decree or requirement
applicable to the manufacturing, packaging, storage, shipment, marketing or sale
of Revlon Products.

     3.1.4 Marketing Efforts. Revlon will promote and market the Revlon Products
in a manner consistent with its efforts for other products and general industry
practice. In connection with these efforts, Revlon will spend in Advertising and
Promotional Expenses during each Contract Year not less than an amount equal to
the amount of Net Sales by Revlon (including permitted sub-licensees) multiplied
by the relevant percentage set forth in Schedule 3.1.4 for such Contract Year;
provided, however, that Revlon shall spend not less than "*Filed Separately with
the Commission*" in Advertising and Promotional Expenses during the first
Contract Year (the "Promotion Commitment").

     3.1.5 Product Launch. Revlon will begin marketing the initial Revlon
Product in the United States not later than the end of the first Calendar
Quarter of 2001.

     3.1.6 Product Standards. The purity of Kinetin utilized by Revlon in
Products shall be no less than "*Filed Separately with the Commission*" with
proof of biological activity

                                       7

<PAGE>

or other efficacy of the Products established by Revlon or its supplier using
such means and at such frequency as Revlon may reasonably determine.

     3.2 Representations and Warranties and Covenants of Senetek. Senetek
represents, warrants and covenants as follows:

     3.2.1 Qualifications and Authorization. Senetek is a public limited company
duly formed, validly existing and in good standing in the United Kingdom with
full corporate power and authority to conduct its business as it is now
conducted and to enter into and perform this Agreement. Senetek is duly licensed
or qualified to do business and is in good standing in California, Delaware and
each other jurisdiction in which its operations or ownership of assets in
connection with this Agreement requires such licensing or qualification.

     3.2.2 No Conflict or Violation. Neither the execution, delivery or
performance of this Agreement, nor compliance by Senetek with any of the
provisions hereof, will (i) violate or conflict with any provision of the
Certificate of Incorporation and Bylaws of Senetek, (ii) violate, conflict with,
or result in a breach of any provision of, or constitute a default (or an event
which, with notice or lapse of time or both, would constitute a default) under,
or result in a creation of any encumbrance upon any of Senetek's assets under,
any of the terms, conditions or provisions of any material contract,
indebtedness, note, bond, indenture, security or pledge agreement, commitment,
license, lease, franchise, permit, agreement, or other instrument or obligation
to which Senetek is a party, or (iii) violate any statute, rule, regulation,
ordinance, code, order, judgment ruling, writ, injunction, decree or award
applicable to Senetek, except, in the case of each of clauses (i), (ii) and
(iii) above, for such violations, conflicts, breaches, defaults or creations of
encumbrances which, in the aggregate, would not have material adverse effect on
the business of Senetek or its ability to perform this agreement.

     3.2.3 Patents. Senetek owns the Patents and either owns or holds licenses
for the use of the Documentation and Know How and has the full and unrestricted
right to license them to Revlon as provided in this Agreement. Senetek has no
knowledge of the existence of any patent or patent applications owned or filed
by any Person other than Senetek that would prevent Revlon from making, having
made, or selling Products under the Patents within the Market Channels and
respective Territories set forth in and otherwise subject to the terms of this
Agreement. The Patents issued by the United States Patent Office are valid and
enforceable in the United States and, to the knowledge of Senetek, the Patents
issued by jurisdictions outside the United States are valid and enforceable in
such jurisdictions. As of the date of this Agreement, Senetek has entered into
no material license agreement with respect to the Patents except as disclosed on
Schedule 3.2.3. Except as disclosed on Schedule 3.2.3, Senetek is not as of the
--------------                         --------------
date of this Agreement involved in any material dispute with respect to the
agreements identified on such schedule.

     3.2.4 Product Claim Substantiation; Testing Data. Senetek has made
available to Revlon all formal research reports prepared by or for Senetek with
respect to the utilization of Kintetin as a skin care product pursuant to the
Patents. All such reports are Senetek Confidential Information. Senetek has made
available to Revlon all currently existing and will continue to make available
all Product claim substantiation and safety testing data, including that
conducted at UC Irvine, and all marketing materials related to the Products,
including, without limitation,

                                       8

<PAGE>

copies of "results" photographs taken by Canfield Scientific, as may be
reasonably necessary to permit Revlon to promote the Products; provided,
however, that Senetek shall not be required to disclose such information if
doing so would violate agreements with others and it has used Best Efforts to
obtain a waiver or amendment of such provisions to permit such disclosure.

4. CONFIDENTIAL INFORMATION AND ANNOUNCEMENTS

     4.1 Senetek Confidential Information. Revlon shall not (a) use Senetek
Confidential Information except to perform its obligations under this Agreement,
or (b) disclose Senetek Confidential Information to any Person (except to its
employees and agents who reasonably require same for the purpose hereof and who
are bound to Revlon by the same obligations as to confidentiality) without the
express written permission of Senetek, unless such disclosure is required by
order of a court of competent jurisdiction.

     4.2 Revlon Confidential Information. Senetek shall not (a) use Revlon
Confidential Information except to perform its obligations under this Agreement,
or (b) disclose Revlon Confidential Information to any Person (except to its
employees and agents who reasonably require same for the purpose hereof and who
are bound to Senetek by the same obligations as to confidentiality) without the
express written permission of Revlon, unless such disclosure is required by
order of a court of competent jurisdiction.

     4.3 No License. The furnishing of Confidential Information by one party to
the other shall not constitute any grant, option or license to the other under
any patent or other rights now or hereafter held by the furnishing party.

     4.4 Announcements. The parties will issue an agreed upon press release upon
the execution of this Agreement in the Form set forth in Schedule 4.3. Except
                                                         -------------
for such release and except as may otherwise be required by law or the listing
rules of any exchange on which either party's securities may be listed or
quoted, for which the releasing party shall provide prior notice to the other
party and the opportunity to comment on any required disclosure, neither party
will disclose the terms of this Agreement to any other Person; provided,
however, that each party may make such disclosure of the terms of this Agreement
to its employees and agents as is necessary to permit such party to perform its
obligations under this Agreement; provided further that any such employee or
agent agrees to maintain the confidentiality of this Agreement; provided further
that Senetek may make such disclosures of the terms of this Agreement as are
necessary to enter into license and other agreements that do not conflict with
the terms of this Agreement. Revlon acknowledges that this Agreement may be
deemed to be "material contracts" as that term is defined by Item 601(b)(10) of
Regulation S-K, and that the Company may therefore be required to file such
documents as exhibits to reports or registration statements filed under the
Securities Act or the Exchange Act. Revlon further agrees that the status of
such documents and materials as material contracts shall be determined solely by
the Company, in consultation with its counsel except that Senetek will redact
commercial terms (such as License Fee, Royalty Rate, Minimum Sales and Royalty
and Promotion Commitment) and file for confidential treatment, in both cases, to
the extent permitted by law. Notwithstanding the restrictions set forth in
Section 4.1 and 4.2. Either party may disclose the results of any clinical
studies or other technical data concerning the Products conducted by it and,
with the consent of the other party which shall not be unreasonably withheld or
delayed, conducted by the other party; provided, however, that such

                                       9

<PAGE>

permitted disclosures to the extent made by Revlon shall not be used to make
comparative effectiveness claims on the basis of concentration levels of
Kinetin.

     4.5 Release from Restrictions. The restrictions set forth in Sections 4.1
and 4.2 shall not apply to Revlon or Senetek Confidential Information disclosed
to the other party (i) that a party rightfully possessed before it received the
information from the other as evidenced by written documentation; (ii) that
subsequently becomes publicly available through no fault of that party; (iii)
that is subsequently furnished rightfully to that party by a third party (no
Affiliate of Revlon or Senetek shall be considered to be a third party) not
known to be under restrictions on use or disclosure; or (iv) that is
independently developed by an employee, agent or contractor of such party.

     4.6 Survival. The provisions of this Article 4 shall survive termination of
this Agreement and continue thereafter for a period of five (5) years; provided,
however, that Revlons obligations with respect to any Senetek Confidential
Information that is Documentation or Know-How shall survive until the expiration
of the last to expire of the Patents.

5. BOOKS AND RECORDS; DISPUTE RESOLUTION

     5.1 Royalties. Revlon shall keep (and shall cause any permitted
sub-licensee to keep) books and records sufficient to permit Senetek to verify
its calculation of all royalties due under this Agreement. Such books and
records shall be preserved for a period not less than two (2) years after they
are created during and after the Term of this Agreement. Revlon shall use Best
Efforts to permit Senetek, within thirty (30) days of its request, to review all
the books and records (including those of any sub-licensee) at a single United
States location to verify the accuracy of Revlon's accounting for royalties.
Such review may be performed by any employee of Senetek as well as by any
attorney or licensed certified public accountant designated by Senetek, upon
reasonable notice and during regular business hours. Senetek shall conduct no
more than one (1) such royalty review during any Contract Year unless any prior
review showed material underpayment of royalties to Senetek, in which case
Senetek may conduct no more than two (2) royalty reviews during any contract
year.

     5.2 Disputes. All disputes between the parties to this Agreement shall be
subject to and resolved in accordance with the terms of Schedule 5.2, which
                                                        ------------
shall be binding on the parties.

6. INDEMNIFICATION, INSURANCE AND LIMITS ON LIABILITY

     6.1 Indemnification by Revlon. Revlon shall defend, indemnify, and hold
harmless Senetek, its officers, agents, employees and affiliates from any loss,
claim, action, damage, expense or liability (including defense costs and
attorneys' fees) (collectively, "Claims") arising out of or related to a breach
or alleged breach of any representation, warranty or covenant made by Revlon
herein, or the manufacture, handling, possession, marketing, sale or other use
of Revlon Products, except insofar as such claims are related to or arise from
Senetek's negligence or breach of any representation, warranty or covenant made
by Senetek under this Agreement.

     6.2 Indemnification by Senetek. Senetek shall defend, indemnify, and hold
harmless Revlon, its officers, agents, employees and affiliates from any Claims
arising out of or related to a breach or alleged breach of any representation,
warranty, or covenant made by Senetek herein,

                                       10

<PAGE>

except insofar as such claims are related to or arise from Revlon's negligence
or breach of any representation, warranty or covenant made by Revlon under this
Agreement.

     6.3 Insurance. Revlon shall maintain at its expense commercial general
liability insurance (including products liability coverage) in a principal
amount of not less than the coverage generally maintained by Revlon in the
ordinary course, but in no event shall Revlon be required to maintain coverage
in excess of "*Filed Separately with the Commission*"per occurrence and "*Filed
Separately with the Commission*" in the annual aggregate. Such policy shall name
Senetek as an additional insured. Within thirty (30) calendar days after the
date of this Agreement, Revlon shall furnish to Senetek a certificate evidencing
such insurance. Senetek may elect not to ship any product to Revlon or to
suspend the license granted hereunder until such insurance is in place and the
certificate of coverage is provided, and may thereafter suspend shipment or the
license granted hereunder if it reasonably believes such insurance is not in
place until Revlon provides Senetek reasonable assurance that such coverage is
in place without any gap in coverage during the Term and will be maintained as
required by this Agreement.

     6.4 No Consequential Damages. Except for claims that include consequential
damages paid to Persons that are not Affiliates of an indemnified party, neither
party shall be liable to the other for consequential damages, lost profits,
injury to reputation or similar claims; provided, however, that nothing in this
sentence shall be construed to in any way limit Revlon's obligation to pay the
royalties and other amounts due to Senetek under this Agreement. UNDER NO
CIRCUMSTANCES SHALL SENETEK OR ITS AFFILIATES HAVE ANY LIABILITY ARISING FROM
THIS AGREEMENT IN EXCESS OF THE HIGHEST AGGREGATE AMOUNT PAID AS ROYALTIES OVER
THE COURSE OF ANY THREE CONSECUTIVE CONTRACT YEARS; PROVIDED, HOWEVER, THAT IN
THE CASE OF LIABILITY FOR A BREACH OF THE REPRESENTATIONS SET FORTH IN SECTIONS
3.2.3 AND 3.2.4 OF THIS AGREEMENT OR A BREACH OF THE REPRESENTATIONS SET FORTH
IN SECTION 3.2.2 OF THIS AGREEMENT THAT MATERIALLY ADVERSELY EFFECTS SENETEK'S
ABILITY TO PERFORM ITS OBLIGATIONS UNDER THIS AGREEMENT, SUCH LIMIT OF LIABILITY
SHALL BE INCREASED BY THE AMOUNT OF THE LICENSE FEE. Each party acknowledges and
agrees that, but for the limitations of liability set forth in this Section, the
other party would not have entered into this Agreement upon the terms set forth
herein and that such limitations are a material part of this Agreement.

     6.5 Recalls. In the event any Revlon Product(s) must be recalled from
distribution by reason of failure to meet any requirements of law or otherwise,
Revlon shall have the sole responsibility to effect the recall. Senetek shall
use its reasonable Best Efforts to cooperate with Revlon in implementing any
such recalls to the extent such cooperation is necessary to effect the recall.
Senetek shall be entitled to indemnification by Revlon as set forth in Section
6.1.

7. Infringement

     7.1 Notification of Infringement. During the Term, each party shall
promptly advise the other in writing of any infringement, imitation or act by
third parties inconsistent with ownership or any act of unfair competition by
third parties (any of the foregoing shall be referred to as an "infringement")
relating to any of the Patents or the Know-How wherever and whenever such
infringement or act shall come to the attention of such party. Senetek agrees
promptly to

                                       11

<PAGE>

take such commercially reasonable action as is required to restrain such
infringement or otherwise enforce the rights in the Patents or the Know-How and
Revlon shall cooperate fully with Senetek in such action and, if so requested by
Senetek, shall join with Senetek as a party to any such action brought by
Senetek. Senetek shall bear all expenses in connection with the foregoing,
although Revlon may be represented by counsel of its own choice, at its own
expense, in any such suit or proceeding brought by Senetek should Revlon so
choose. In the event that within a reasonable time after Senetek becomes aware
of such infringement, Senetek fails to take appropriate and diligent action with
respect to such infringement action that is reasonably required, Revlon shall
have the right, to the extent permitted by law, to institute an action for
infringement at its own expense, and in its own name, or in the name of any of
its Affiliates and the right to enforce and collect any judgment thereon.
Senetek may be represented by counsel of its own choice, at its own expense, in
any action so brought by Revlon to restrain such infringement should it so
choose. Senetek, at its own expense, shall cooperate fully with Revlon in such
action and, if so requested by Revlon, at Revlon's expense shall join with
Revlon as a party to any such action brought by Revlon.

     7.2 Recovery. Any recovery by either party as a result of any claim,
demand, litigation or other action contemplated by Section 7.1 or settlement
thereof shall first be used to reimburse each party for the reasonable costs of
the action borne by such party (or, if the recovery is less than the aggregate
costs of such action, shall be distributed between the parties in proportion to
the costs of the action borne by each of the parties), with the remaining
amount, if any, to be paid to the party bringing the action.

8. TERM AND TERMINATION

     8.1 Term. The term of this Agreement shall be the Term unless early
terminated pursuant to this Article 8.

     8.2 Termination for Cause. Each party shall have the right to terminate
this Agreement at any time upon written notice to the other in the event (i) the
other party fails to perform any material obligation and such failure continues
for a period of thirty (30) days after notice thereof with respect to a payment
failure or, with respect to any other failure, such failure continues for a
period of sixty (60) days after notice thereof or (ii) the other party is
declared insolvent or bankrupt by a court of competent jurisdiction, or a
voluntary petition of bankruptcy is filed in any court of competent jurisdiction
by the other party, or the other party makes or executes any assignment for the
benefit of creditors.

     8.3 Failure to Meet Minimum Sales Levels or Promotion Commitments. Senetek
may terminate this Agreement upon ninety (90) days written notice to Revlon
given within ninety (90) days after the close of any Contract Year in which
Revlon (i) fails to meet the Minimum Sales Levels for such Contract Year, or
(ii) fails to meet the Promotion Commitment for two (2) consecutive Contract
Years; provided, however, that Senetek shall have no right to terminate pursuant
to Section 8.3(i) if (a) Revlon has paid to Senetek for that Contract Year
royalties in an amount equal to, or more, than the Minimum Royalty for that
Contract Year or (b) within thirty (30) days of the end of the Contract Year in
which the failure to meet the Minimum Sales Levels occurs Revlon pays Senetek an
amount equal to the Minimum Royalty for the applicable Contract Year less the
amount of royalties actually paid with respect to such Contract Year.

                                       12

<PAGE>

     8.4 Termination for Convenience. Revlon may terminate the Agreement
effective at the end of any Contract year after the fifth Contract Year upon
written notice given to Senetek not less than 180 days prior to the end of the
then current Contract Year.

     8.5 Bankruptcy of Senetek. The parties hereby agree that licenses under
this Agreement are licenses of intellectual property as defined in Section
101(35A) (formerly Section 101(56)) of the Bankruptcy Code, and that this
license agreement is governed by Section 365(n) of the Bankruptcy Code. Senetek
hereby agrees that in the event this Agreement is assigned to any third party in
any bankruptcy action by Senetek, such assignee must assume all of Senetek's
obligations under this Agreement.

9. MISCELLANEOUS

     9.1 Service on Advisory Panel. Revlon agrees to serve on Senetek's panel
that advises Senetek with respect to the Kinetin and related products.

     9.2 Method of Payments. All payments due under this Agreement shall be paid
in U.S. Dollars in cash by a check drawn on a United States bank or by wire
transfer of immediately available funds to Senetek in the United States. Late
payments shall be subject to a monthly processing fee of "*Filed Separately with
the Commission*" of the amount overdue or, if such amount is not permitted by
law, the maximum amount permitted by law. Exchange rates used to convert local
currency sales to U.S. dollars shall be the month end exchange rates of New York
banks for buying U.S. dollars as published in the Wall Street Journal for the
last month of the quarter in respect of which payments are due.

     9.3 Taxes. All taxes due with respect to the manufacture or sale of Revlon
Product shall be paid by Revlon except for taxes due from and in respect of the
income of Senetek (an "Income Tax"). If Senetek is required to collect and remit
any tax with respect to the license granted to Revlon or any manufacture of
Revlon Product (other than an Income Tax), Senetek shall be entitled to collect
the amount of such tax from Revlon within 30 days of the date any such tax is
due.

     9.4 No Joint Venture. It is not the intent of the parties hereto to form
any partnership or joint venture. Each Party shall, in relation to its
obligations hereunder, act as an independent contractor, and nothing in this
Agreement shall be construed to give either party the power or authority to act
for, bind or commit the other.

     9.5 Governing Law. This Agreement shall be governed by and interpreted in
accordance with the laws of the State of New York (regardless of that or any
other jurisdiction's choice of law principles).

     9.6 No Assignment. Neither party to this Agreement may assign its rights or
obligations under this Agreement without the prior written consent of the other
party to this Agreement; provided, however, that either party may assign its
rights to an Affiliate or to any successor by merger, consolidation, sale of
stock or the sale of substantially all of the assets of such party; provided
further, that no such permitted assignment or sublicense shall relieve the

                                       13

<PAGE>

assigning party of its obligations under this Agreement. Revlon shall have no
right to sublicense any of its rights under this Agreement except that Revlon
may sublicense its rights granted under Section 2.1 in Territories other than
the United States. No such permitted sublicense shall relieve Revlon of any of
its obligations under this Agreement, including the obligation to pay royalties
with respect to Product sold by its sub-licensees. Any permitted sublicense
shall require that the sub-licensee comply with the terms of this Agreement and
shall name Senetek as a third-party beneficiary with rights of enforcement. No
sub-licensee shall have any right to grant additional sublicenses, and any
attempt to grant such a further sublicense shall be void.

     9.7 Force Majeure. No party hereto shall be liable to any other in damages
for, nor shall this Agreement be terminable by reason of, any delay or default
in such party's performance hereunder if such delay or default is caused by
conditions beyond such party's control including, but not limited to, acts of
God, regulation or law or other action of any government or any agency thereof,
war, insurrection, civil commotion, destruction of production facilities or
materials by earthquake, fire, flood or storm, labor disturbances, epidemic, or
failure of suppliers, public utilities or common carriers. Each party hereto
agrees to promptly notify the other party of any event of force majeure under
this Section 9.7 and to employ Best Efforts towards prompt resumption of its
performance hereunder if such performance is delayed or interrupted by reason of
such event. In the absence of a force majeure event involving material
impairment or destruction of manufacturing capability or supply chain for
Product, no force majeure event shall be deemed to excuse the failure of Revlon
to meet the Minimum Sales Levels or Promotion Commitment applicable to any
Contract Year.

     9.8 Notices. Unless otherwise provided herein, any notice required or
permitted to be given hereunder (a "Notice") shall be mailed by certified mail
or generally recognized express courier service with signature required for
delivery, postage prepaid, sent by facsimile transmission or delivered by hand
to the party to whom such Notice is required or permitted to be given hereunder.
If mailed, any such Notice shall be deemed to have been given as of the date of
receipt, as evidenced by the date appearing on the delivery notice. If delivered
by hand, any such Notice shall be deemed to have been given when received by the
party or agent of such party to whom such Notice is given, as evidenced by
written and dated receipt of the receiving party.

                  All Notices to Revlon shall be addressed as follows:

                  Revlon Consumer Products Corporation
                  625 Madison Avenue
                  New York, New York 10022
                  Attn.:  Senior Vice President and General Counsel
                  Facsimile: (212) 527-5693

                  All Notices to Senetek shall be addressed as follows:

                  Senetek PLC
                  620 Airpark Road
                  Napa, California  94553
                  Attn: Frank Massino

                                       14

<PAGE>

                  Facsimile: (707) 257-8193

                  and

                  Latham & Watkins
                  1001 Pennsylvania Avenue, N.W.
                  Suite 1300
                  Washington, D.C. 20004
                  Attn.:  Kevin C. Boyle
                  Facsimile: 202-637-2201

Either party may change the address to which any Notice to it is to be addressed
by notification to the other party as provided herein.

     9.9 Captions. The captions in this Agreement are solely for convenience of
reference and shall not be used for purposes of interpreting or construing the
provisions hereof.

     9.10 Severability. Should any part or provision of this Agreement be held
unenforceable or in conflict with the applicable laws or regulations of any
jurisdiction, the invalid or unenforceable part or provision shall be replaced
with a provision which accomplishes, to the extent possible, the original
business purpose of such part or provision in a valid and enforceable manner,
and the remainder of this Agreement shall remain binding upon the parties
hereto.

     9.11 Waiver. No failure on the part of any party hereto to exercise, and no
delay in exercising, any right, privilege or power hereunder shall operate as a
waiver or relinquishment thereof; nor shall any single or partial exercise by
any party hereto of any right, privilege or power hereunder preclude any other
or further exercise thereof, or the exercise of any other right, privilege or
power.

     9.12 Entire Agreement. This Agreement together with its Schedules and
Exhibits and the Securities Purchase Agreement constitute the entire agreement
and understanding between the parties hereto with respect to the subject matter
of this Agreement and shall supersede any prior agreements, negotiations,
understandings, representations, statements and writings relating thereto. This
Agreement may not be amended or modified except in a writing signed by a duly
authorized officer of the party against whom enforcement of such amendment is
sought.

     9.13 Counterparts. This Agreement may be executed in one or more
counterparts by exchange of facsimile copies of signature pages, each of which
will be deemed an original and all of which together will constitute one and the
same instrument.

     9.14 Document Preparation. The Parties acknowledge that this Agreement is a
product of extensive negotiations and that no inference should be drawn
regarding the preparation of this document.

                  To evidence this Agreement, the parties have caused their duly
authorized representatives to execute this Agreement as of the Agreement Date.

                                       15

<PAGE>

              REVLON CONSUMER PRODUCTS CORPORATION

              By:      /s/ Wade H. Nichols
                 -----------------------------------------

              Name:    Wade H. Nichols
                   ---------------------------------------

              Title:   Executive Vice President
                    --------------------------------------

              SENETEK, PLC

              By:      /s/ Frank J. Massino
                 --------------------------------------------------

              Name:    Frank J. Massino
                   ---------------------------------------

              Title:   Chairman and Chief Executive Officer
                   ----------------------------------------

                                       16

<PAGE>

                                  SCHEDULE 1.9

                               DISCLOSURE SCHEDULE

None.

<PAGE>

                                  SCHEDULE 1.10

                    "*Filed Separately with the Commission*"

                                       19

<PAGE>

                                  SCHEDULE 1.19

                    "*Filed Separately with the Commission*"

                                       20

<PAGE>

                                  SCHEDULE 1.20

                    "*Filed Separately with the Commission*"

                                       21

<PAGE>

                                  SCHEDULE 1.21

                    "*Filed Separately with the Commission*"

                                       22

<PAGE>

                                  SCHEDULE 2.1

                            AUTHORIZED MARKET CHANNEL

                                       AND

                                    TERRITORY
<TABLE>
<CAPTION>

------------------------------------------------------------ ---------------------------------------------------------
                      MARKET CHANNEL                                                TERRITORY
------------------------------------------------------------ ---------------------------------------------------------
<S>                                                          <C>
Mass Market (drug stores, chain drug stores, food stores,    World-wide (except for the following territories now
chain food stores, mass volume retailers (such as Kmart,     licensed to Obagi:  Japan, China (including Hong Kong),
Walmart and Target), and food combo), J.C. Penny, and        Republic of Korea, Democratic People's Republic of
Category Killers such as Ulta 3 and Cosmetics Plus (but      Korea, Singapore, Cambodia, Philippines, Vietnam each
expressly excluding market channels occupied by The Body     country which shall automatically become a Territory of
Shop and any sales to Sephora, Bath & Body Works, Garden     Revlon if the present license terminates or expires
Botanika, Origins, Aveda and The Limited Group of            with respect to such country and Revlon launches
companies) (collectively, the "Mass Market")                 Product in the Sub-Territory to which the country
                                                             belongs within 24 months after notice from Senetek of
                                                             such expiration or termination.)
------------------------------------------------------------ ---------------------------------------------------------
</TABLE>

The right to sell in the Market Channel shall include the right to make sales
from websites operated (i) by customers within the Market Channel or (ii) by
Revlon in serving customers within the Market Channel. Nothing in this Agreement
shall be construed to exclude internet sales by other licensees of Senetek or by
Senetek.

If Revlon enters into a binding agreement with Sears, Roebuck & Co. ("Sears")
for the sale of cosmetics to Sears in its full line stores (which agreement does
not preclude the sale of Products at Sears) within one year of the date of this
Agreement and thereafter Product is available for sale in Sears full line stores
within two years of the date of this Agreement, the Market Channel shall include
Sears.

                                     23

<PAGE>

                                 SCHEDULE 3.1.4

                    "*Filed Separately with the Commission*"

                                       24

<PAGE>

                                 SCHEDULE 3.2.3

                            OTHER LICENSE AGREEMENTS

1. ICN Pharmaceuticals

2. Obagi

3. Osmotics*

4. The Body Shop

"*Filed Separately with the Commission*".

                                       25

<PAGE>

                                  SCHEDULE 5.2

                               DISPUTE RESOLUTION

                  Any dispute between the parties arising out of or relating to
this Agreement, including with respect to the interpretation of any provision of
this Agreement or with respect to the performance by Revlon or Senetek, shall be
resolved as provided in this Schedule 5.2.

                  (a)      Informal Dispute Resolution.
                           ---------------------------

                  The parties shall in good faith first attempt to resolve their
dispute on an informal basis through discussions between a designated
representative of each party, as follows. Either party may initiate this
informal resolution process (the "Disputing Party") by sending a notice to the
other party outlining to such other party the nature of the dispute and the name
and contact information of the officer of the Disputing Party who shall act as
its designated representative. Within (7) days of receipt of such notice, the
receiving party shall by notice designate an officer who shall act as that
party's designated representative. The designated representatives shall meet at
a mutually acceptable time and place within fourteen (14) days of the date the
initial notice was received and thereafter as often as they reasonably deem
necessary. No communication made during this period between the parties
concerning the dispute may be used by either party in any subsequent proceeding
for any reason.

                  (b)      Arbitration.
                           -----------

                  If the parties are unable to resolve the dispute informally,
within twenty-one (21) days of the date the initial notice was received, either
party may commence a mandatory and binding arbitration concerning such dispute,
in accordance with the following procedures:

                  (i)      Selection of Arbitrator. The party making demand for
                           -----------------------
arbitration (the "Disputing Party") shall notify the American Arbitration
Association (the "AAA") and the other party in writing describing in reasonable
detail the nature of the dispute (the "Demand for Arbitration"), and shall
request that the AAA furnish a list of five (5) possible arbitrators who shall
have substantial experience in the area of patent licensing and shall otherwise
be qualified to competently address the issues presented. Each party shall have
fifteen (15) days to reject two (2) of the proposed arbitrators. If only one
individual has not been so rejected, he or she shall serve as arbitrator. If two
(2) or more individuals have not been so rejected, then the parties shall
promptly mutually select the arbitrator from the remaining pool of possible
arbitrators; provided, however, that if the parties are unable to agree on such
selection within ten (10) days after notification by the AAA of the need to make
such selection, then the AAA shall select the arbitrator from the remaining pool
of possible arbitrators.

                  (ii)     Conduct of Arbitration.
                           ----------------------

                  (A)      The arbitrator shall allow reasonable discovery in
the forms permitted by the United States Federal Rules of Civil Procedure,
consistent with the purpose of the arbitration. Such discovery shall be
completed no later than sixty (60) days following the appointment of the
arbitrator.

                                       26

<PAGE>

                  (B)      Following the conclusion of the discovery period, the
arbitration hearing shall be commenced promptly and conducted expeditiously,
with each of the parties being limited to no more than a total of five (5)
business days for the presentation of its case, including any rebuttal or
cross-examination. Unless otherwise agreed by the parties, the arbitration
hearing shall be conducted on consecutive business days. Strict rules of
evidence shall not be applied in the arbitration hearing. The arbitrator shall
control the presentation of evidence and accord it such weight as the arbitrator
deems appropriate. Cross-examination of witnesses and rebuttal testimony may be
permitted.

                  (C)      Each party may submit one pre-arbitration brief (of
not more than twenty (20) pages (excluding exhibits)), and a list of proposed
witnesses setting forth a brief summary of their testimony, no later than five
(5) days prior to the commencement of the arbitration hearing, and may also
submit one post-arbitration hearing brief (of not more than ten (10) pages
(excluding exhibits)) no later than five (5) days after the close of the
arbitration hearing. A copy of any brief or document submitted to the arbitrator
shall also be served on the other party.

                  (D)      The arbitrator shall have no power or authority to
amend or disregard any provision of this Schedule 5.2 or any other provision of
the Agreement (in particular, the arbitrator shall not have the authority to
exclude the right of a party to terminate the Agreement when a party would
otherwise have such rights or to assess damages in excess of or different than
those provided under the Agreement).

                  (E)      Except when a conflict exists between the terms of
the Agreement and the rules of commercial arbitration of the AAA in effect at
the time of arbitration, the arbitrator shall use the rules of commercial
arbitration of the AAA in effect at the time of the arbitration.

                  (iii)    Replacement of Arbitrator. Should the arbitrator
                           -------------------------
refuse or be unable to proceed with arbitration proceedings as called for by
this Schedule 5.2, such arbitrator shall be replaced by an arbitrator selected
according to the procedures stated above.

                  (iv)     Authority of Arbitrator to Rule. The parties hereby
                           -------------------------------
agree and consent that the arbitrator shall be fully authorized and empowered to
(i) permit and rule on motions of summary judgment made by either of the parties
and (ii) award injunctive relief. The ruling of the arbitrator, including on any
motion of summary judgment or concerning any award of injunctive relief, shall
be final and binding on the parties, and may be confirmed in any court of
competent jurisdiction.

                  (v)      Findings and Conclusions. The arbitrator rendering
                           ------------------------
judgment upon disputes between the parties may prepare and distribute to the
parties a writing describing the findings of fact and conclusions of law
relevant to the judgment and award and containing an opinion setting forth the
reasons for the giving or denial of any award. The award of the arbitrator shall
be final and binding on the parties, and judgment thereon may be entered in a
court of competent jurisdiction.

                  (vi)     Place of Arbitration. Arbitration, including any
                           --------------------
necessary hearings hereunder, shall be held in Chicago, Illinois. If the parties
agree, arbitration hearings may be held in another location.

                                       27

<PAGE>

                  (vii)    Time of the Essence. The arbitrator is instructed
                           -------------------
that time is of the essence in the arbitration proceeding, and that the
arbitrator shall have the right and authority to issue monetary sanctions
against either of the parties if, upon a showing of good cause, that party is
unreasonably delaying the proceeding. The arbitrator shall render his or her
judgment or award within fifteen (15) days following the conclusion of the
hearing. Recognizing the express desire of the parties for an expeditious means
of dispute resolution, the arbitrator shall limit or allow the parties to expand
the scope of discovery as may be reasonable under the circumstances. In no event
shall the period of time from the date of delivery to the other party of a
party's demand for arbitration to the arbitrator's rendering of his or her
judgment exceed one hundred eighty (180) days.

                  (viii)   Confidentiality. The parties agree that the existence
                           ---------------
of a dispute, any efforts or proceedings to resolve a dispute, whether informal
or pursuant to arbitration, and any rulings or decisions issued by the
arbitrator pursuant to this Schedule 5.2, shall be held in confidence in
accordance with the terms and conditions of Article 15 of this Agreement.

                  (ix)     Costs and Expenses. The parties shall jointly and
                           ------------------
equally pay the expenses of the arbitrator and  administrative costs assessed
by the AAA.

                  (c)      Litigation.
                           ----------
                  (i)      Immediate Injunctive Relief. The parties agree that
                           ---------------------------
the only circumstance in which disputes between them shall not be subject to the
arbitration provisions of this Schedule 5.2 is where a party makes a good faith
determination that the party needs and is entitled to receive a temporary
restraining order or other emergency injunctive relief in order to protect its
interest during the pendency of an arbitration proceeding. If a party files a
pleading with a court seeking immediate injunctive relief and this pleading is
challenged by the other party and the injunctive relief sought is not awarded in
substantial part, the party filing the pleading seeking immediate injunctive
relief shall pay all of the costs and attorneys' fees of the party successfully
challenging the pleading.

                  (ii)     Jurisdiction. The parties consent to jurisdiction and
                           ------------
venue in the Northern District of Illinois for all litigation that may be
brought, subject to the requirement for arbitration hereunder, arising out of or
relating to this Agreement, including with respect to the interpretation of any
provision of this Agreement or with respect to the performance by Licensee or
Licenser. The parties further consent to the jurisdiction of any state or
provincial court located within a district which encompasses assets of a party
against which judgment has been rendered, either through arbitration or through
litigation, for the enforcement of such judgment or award against the assets of
such party.

                  (d)      Governing Law.
                           -------------
                  Disputes subject to this Schedule 5.2, and all proceedings to
resolve such disputes, shall be governed by and proceed in accordance with, the
laws of the jurisdiction whose laws govern the Agreement.

                                       28<PAGE>

                                                                   Exhibit 10.51

                       PRODUCTION AND MARKETING AGREEMENT
                       ----------------------------------

*** Confidential treatment has been requested as to certain portions of this
agreement. Such omitted confidential information has been filed separately with
the Securities and Exchange Commission pursuant to Rule 24b-2 under the
Securities Exchange Act of 1934, as amended, and the Commission's rules and
regulations promulgated under the Freedom of Information Act, pursuant to a
request of confidential treatment.

     This Production and Marketing Agreement (this "Agreement"), dated and
effective August 15, 2000, is between SENETEK PLC, a United Kingdom Company,
whose principal office is located at 23 Place Street, London, SW1E, 5HW England
(hereinafter referred to as "Senetek"), and SIGNET LABORATORIES, INC., a
Delaware corporation having its principal place of business at 180 Rustcraft
Road, Dedham, Massachusetts 02026 (hereinafter referred to as "Signet").

                                 WITNESSETH THAT
                                 ---------------

     WHEREAS, Senetek has a ten-year exclusive worldwide license to certain cell
lines (hereinafter the "Cell Lines"), to wit:

          1. Those certain cell lines designated "4G8" and "6E10" more
     particularly described in an Agreement by and between Research Foundation
     for Mental Hygiene, Inc. (hereinafter referred to as RFMH) and Senetek
     dated by Senetek July 21, 1994 and dated by RFMH July 12, 1994 (hereinafter
     referred to as the "Basic Agreement/ License"), as amended by Amendment #1
     dated by Senetek August 1, 1995 and dated by RFMH July 28, 1995;

          2. The monoclonal antibody designated "525 Reactive to PHF" more
     particularly described in an Agreement dated by Senetek August 1, 1995 and
     dated by RFMH July 28, 1995, said Agreement being attached as "Appendix
     A-1" to the Basic Agreement/License;

          3. Those certain cell lines designated "339 Reactive to PHF" and "3F4
     Reactive to Prion PrP (human and hamster)" more particularly described in
     an Agreement dated by Senetek August 30, 1995 and dated by RFMH May 22,
     1995, said Agreement being attached as "Appendix A-2" to the Basic
     Agreement/License;

          WHEREAS, the Basic Agreement/License provides for a ten-year exclusive
     worldwide license to cell line products (hereinafter the "Cell Line
     Products"), attached hereto as Exhibit "A" to wit: the monoclonal
     antibodies produced in any form by using the Cell Lines, including, but not
     limited to pure, Fab fragment, ascites fluid, tissue culture fluid,
     modified or conjugated (i.e., enzymes, biotin, florescent or any other
     form);

          WHEREAS, Senetek desires to grant to Signet and Signet desires to
     secure from Senetek rights to manufacture, package, promote and sell the
     Cell Line Produces--such activities to be performed in accordance with the
     terms and conditions set forth herein and subject to and in accordance with
     the terms of the Basic Agreement;

     NOW, THEREFORE, in consideration of the mutual covenants herein recited,
the parties hereby agree as follows:

<PAGE>

     1. Grant.
        ------

          1.1 Right to Manufacture, Package, Promote and Sell. Upon the terms
              -----------------------------------------------
and conditions set forth herein, Senetek hereby grants to Signet a worldwide
excusive right to manufacture, package, promote and sell the Cell Line Products.

          1.2 Acceptance by Signet. Signet hereby accepts the foregoing grant of
worldwide exclusive rights to manufacture, package, promote and sell the Cell
Line Products.

          1.3 Not a License. This grant shall not be construed as a license, by
implication or otherwise, under any applications or rights to which shall remain
with Senetek in accordance with the terms of the Basic Agreement/License.

     2. Term of Agreement. The term of this Agreement shall be contemporaneous
with the Basic Agreement/License and any and all renewals/extensions thereof,
unless terminated as hereinafter provided.

     3. Sharing of Revenues.
        --------------------

     Level 1 From the first "*Filed Separately with the Commission*" of annual
     -------
     sales revenues received by Signet from sales of Cell Line Products, Signet
     shall retain "*Filed Separately with the Commission*" of annual sales
     revenues, plus reasonable production costs consistent with Senetek's
     agreement with Covance Research Products, Inc., plus reasonable charges for
     QA/QC compliance not to exceed "*Filed Separately with the Commission*"
     annually, plus sales and distribution taxes [including, but not limited to,
     federal manufacturer's and retailer's excise, state and local sales and use
     taxes and personal property taxes), value-added taxes, public charges,
     tariffs, import duties, quarantine charges or license fees however
     designated, levied or based on such prices (hereinafter referred to as
     "Taxes")]. The remainder of the sales revenues shall be remitted to
     Senetek. Senetek shall be responsible for all fees due to RFMH in
     accordance with the Basic Agreement/ License.

     Level 2 From annual sales revenues in excess of "*Filed Separately with the
     -------
     Commission*" received by Signet from sales of Cell Line Products, Signet
     shall pay "*Filed Separately with the Commission*"of annual sales revenues
     in excess of "*Filed Separately with the Commission*" and all fees due RFMH
     in accordance with the Basic Agreement/License. Signet is responsible for
     costs and expenses incurred in connection with the sale of Cell Line
     Products.

     Level 3 "New Cell Line Products" are described as products which are not
     -------
     listed on Exhibit A, including derivatives of Cell Line Products and
     additional products obtained from RFMH for sale under this agreement. From
     annual sales revenues received by Signet from sales of new Cell Line
     Products, Signet shall pay to Senetek "*Filed Separately with the
     Commission*" of annual sales revenues. Signet is responsible for all costs
     and expenses incurred in connection with the sale of New Cell Line
     Products. Signet shall be responsible for all fees due to RFMH in
     accordance with the Basic Agreement/License. If at any time during the

                                       2

<PAGE>

first three (3) years of this Agreement, a derivative product significantly
impacts sales of Level 1 Cell Line Products, Senetek and Signet may re-negotiate
a revenue-sharing agreement for those derivative products.

4.       Reports.
         -------

     4.1 Reports. Signet agrees to deliver to Senetek and RFMH within thirty
         -------
(30) days after the expiration of each calendar quarter beginning with the
calendar quarter having the first sales date following the date of this
Agreement, an accounting in writing setting forth the net proceeds of sales
during such calendar quarter.

     4.2 Records and Audits. Signet shall keep a true and exact record in
         ------------------
connection with the accounting provided herein, and Senetek shall have the right
once each calendar year beginning with the first report to appoint at no cost to
Signet an independent certified public accountant to whom Signet can have no
reasonable objection, who, during the regular business hours of Signet, may
examine the accounts and records of Signet insofar as they relate to net
proceeds of sales for a period not more than two (2) years preceding the date of
inspection, for the sole purpose of verifying the correctness of any accounting
by Signet, and not for any other purpose. Said accountant shall be under an
obligation of secrecy not to disclose any information (s)he learns except (s)he
may disclose to Senetek any information which relates solely to the accuracy of
reports and payments under this Agreement.

5.       Payments.
         --------

     5.1 Payments. Payments to Senetek from Level 1 revenues and payments to
         --------
Senetek and RFMH from Level 2 and Level 3 revenues, as the case may be, shall be
due and payable thirty (30) days after the expiration of each calendar quarter.

     5.2 Currencies. All payments payable hereunder to Senetek shall be payable
         ----------
in United States Dollars (USD). If foreign exchange is freely available and
remittance of the payments provided herein is not otherwise prohibited, all
royalties due to Senetek hereunder as a result of sales in countries foreign to
the United States shall be converted (for the purpose only of calculation of
such royalties) into its equivalent in USD at the foreign exchange rate for such
foreign funds as reported in the Wall Street Journal at the close of business on
the last business day of the quarterly reporting period.

6.       Representations and Warranties.
         ------------------------------

     6.1 Signet.
         ------

          (i) Signet warrants and represents that Signet shall devote its
faithful, diligent and best efforts to distribute, market, promote and sell the
Cell Line Products, and maintain and enhance the good will of the Cell Line
Products worldwide.

          (ii) Signet warrants and represents to Senetek that it is not, and
shall not hold itself out as, the representative, agent, servant or employee of
Senetek for any purpose. This Agreement creates no relationship of joint
venture, partnership, limited partnership, or agency between the parties.

                                       3

<PAGE>

         (iii) Signet represents and warrants that the execution of this
Agreement by Signet has been duly authorized by all necessary corporate action
of Signet and constitutes the valid and binding obligation of Signet. The
execution of this Agreement by Signet and the consummation of the transactions
contemplated hereby does not conflict with or result in a default under or
breach of: (1) Signet's Articles of Incorporation or By-laws or other
organizational documents; (2) any agreement, indenture, mortgage, contract or
instrument to which Signet is bound or by which any of its properties or assets
is subject; (3) any order, writ, injunction, decree or judgment of any court or
governmental agency applicable to Signet or to which any of its assets is bound;
or (4) any law or regulation applicable to Signet or by which any of its assets
is bound.

         (iv) Signet acknowledges that the Cell Line Products: (1) are the sole
property and confidential information of RFMH; (2) are subject to
confidentiality requirements under the Basic Agreement/License which
requirements also bind Signet; and (3) may be transferred only back to Senetek
or RFMH in accordance with the terms and requirements of the Basic
Agreement/License.

         (v) Signet agrees not to undertake any separate and independent
business relationship with RFMH in the field of neuroscience products during the
term of this Agreement.

     6.2 Senetek.
         -------

          (i) Senetek represents and warrants that it is not in default of any
term, provision or condition of the Basic Agreement/License and that its rights
thereunder are not encumbered in any manner, and the Cell Line Products are free
of any claims for infringement, patent or copyrights and trademarks of third
parties. Senetek also represents and warrants that there is no litigation, claim
or assessment pending or threatened against Senetek contesting Senetek's rights
under the Basic Agreement/License. Senetek hereby indemnifies and will hold
Signet harmless from any and all costs, expenses, claims, attorney's fees and so
forth in regard to all matters which have transpired prior to the execution of
this Agreement now known or hereafter arising from the Basic Agreement/License,
including, but not limited to, any and all claims from RFMH.

         (ii) Senetek represents and warrants that it will terminate its
Manufacturing and Distribution Agreement with Covance Research Products, Inc.
dated September 24, 1999 in accordance with the terms of said Agreement, and
that there is no litigation, claim or assessment pending or threatened against
Senetek on account thereof. Senetek will consult with Signet on the timing of
the thirty (3) day notice of termination required thereunder.

         (iii) Senetek has complied with the terms and conditions of the Basic
Agreement/License, including, but not limited to, all notice requirements and
has received all of the necessary approvals from RFMH regarding the execution of
this Agreement, including without limitation under Section 2.4 of the Basic
Agreement/License, to engage Signet to manufacture, package, promote and sell
the Cell Line Products. Copies of all such approvals in form satisfactory to
Signet will be delivered to Signet simultaneously with the execution of this

                                       4

<PAGE>

Agreement. Senetek will deliver forthwith to Signet any and all documents
and correspondence received by Senetek from RFMH in regard to the bal. Copies of
all such approvals in form satisfactory to Signet will be delivered to Signet
simultaneously with the execution of this Agreement. Senetek will deliver
forthwith to Signet any and all documents and correspondence received by Senetek
from RFMH in regard to the Basic Agreement/License, including, but not limited
to, any and all notices of default delivered by RFMH to Senetek. Senetek hereby
grants to Signet the right to cure any and all such defaults in accordance with
the Basic Agreement/License. In the event a default is based on the failure of
Senetek to comply with the terms of the Basic Agreement/License and there is an
expenditure of time and money by Signet to cure said default, Signet shall have
the right to offset any such expenditure from future payments due from Signet to
Senetek hereunder.

         (iv) Senetek represents and warrants that the execution of this
Agreement by Senetek has been duly authorized by all necessary corporate action
of Senetek and constitutes the valid and binding obligation of Senetek. The
execution of this Agreement by Senetek and the consummation of the transactions
contemplated herby does not conflict with or result in a default under or breach
of: (1) Senetek's Articles of Incorporation or By-laws or other organizational
documents; (2) any agreement, indenture, mortgage, contract or instrument to
which Senetek is bound or by which any of its properties or assets is subject;
(3) any order, writ, injunction, decree or judgment of any court or governmental
agency applicable to Senetek or to which any of its assets is bound; or (4) any
law or regulation applicable to Senetek or by which any of its assets is bound.

7.       Termination.
         -----------

     7.1 Termination by Signet. This Agreement can be terminated by Signet at
         ---------------------
any time upon ninety (90) days written notice to Senetek, if it is determined by
Signet, in its sole and absolute discretion, that the annual sales revenues will
fall below the minimums required by Signet to make this Production and Marketing
Agreement profitable to Signet. In the event of such termination, Signet agrees
to pay to Senetek all amounts due and payable up to the effective date of such
termination. Upon such termination, Signet shall return to Senetek all
antibodies, all technical information, Cell Lines and know-how transferred to
Signet by Senetek. Signet shall have the right to sell any Cell Line Products in
inventory at the time of said termination and shall pay amounts due to Senetek
upon the sale of Cell Line Products in accordance with Section 4.

     7.2 Termination by Senetek. This Agreement may be terminated by Senetek if:
         ----------------------

         (a) Signet shall fail to pay any amounts as provided in Section 4 at
any time when the same become due, and such failure shall continue unremedied
for thirty (30) days after written notice thereof is sent by Senetek to Signet;

         (b) Signet shall at any time become insolvent or make a general
assignment for the benefit of creditors, or if a petition in bankruptcy, or
insolvency, or any reorganization shall be commenced by, against or in respect
of Signet and shall remain undismissed for more than sixty (60) days;

                                       5

<PAGE>

         (c) In the event of breach or default (for reasons other than failure
to pay any amounts due hereunder) by Signet; provided, however, Senetek shall
give written notice of termination by reason of such default. If such default
shall not be cured within ninety (90) days after written notice, the Agreement
shall be terminated at the end of such ninety (90) day period.

         (d) In the event revenues received by Senetek from Signet from
"Level 1", i.e., payments received from "Current Cell Line Products" hereunder
shall be less than "*Filed Separately with the Commission*" for a period of two
(2) successive years, Senetek has the right to terminate this Agreement with
respect to "Current Cell Line Products" only.

8.       Confidentiality. Signet agrees to keep strictly confidential all
         ---------------
material and other information classified as "Confidential" including, but not
limited to, the terms and conditions of the Basic Agreement/License, and
supplied to Signet by Senetek in connection with its performance under this
Agreement. Signet undertakes not to disclose any such "Confidential" materials
or information to any person except as may be necessary for the furtherance of
this Agreement. Signet further agrees to bind its officers and employees, and
any agents, representatives or third parties who have knowledge of or access to
such "Confidential" information to a similar obligation of confidentiality. In
the event of termination of this Agreement, Signet agrees to return any such
"Confidential" materials or information to Senetek and to cause any person to
whom such "Confidential" materials or information has been supplied to do
likewise.

9.       Governing Law and Arbitration: Venue.
         ------------------------------------

     9.1 This Agreement shall be deemed made under, governed by and construed in
accordance with the laws of the State of California, without giving effect to
conflict of laws provisions thereof. The parties agree that the party to this
Agreement prevailing in an action arising from breach of this Agreement or of
any of its provisions shall be entitled to all costs of such suit or action,
including attorneys' fees.

     9.2 Any controversy or claim arising out of or relating to this Agreement
or the breach thereof, shall be settled by arbitration in San Francisco,
California, in accordance with the Rules of the American Arbitration Association
then obtaining, and judgment upon the award rendered by the arbitrator(s) may be
enforced in either the courts of the State of California or the United States
District Court for the District of California, to whose jurisdiction each of the
parties herby consents. Nothing contained herein shall prevent the parties from
seeking injunctive or other equitable relief in the foregoing courts prior to
arbitration.

10.      General.
         -------

     10.1 In the event any proceeding is commenced to enforce this Agreement or
otherwise relating to this Agreement, the prevailing party shall be entitled to
reasonable attorneys' fees and costs incurred in connection therewith.

     10.2 This Agreement may be executed in one or more counterparts, each of
which shall be deemed an original, but all of which together shall constitute
one and the same instrument; however, this Agreement shall be of no force or
effect until executed by both parties.

                                       6

<PAGE>

     10.3 Captions and Section and Subsection headings used herein are for
convenience only, and are not a part of this Agreement and shall not be used in
construing it.

     10.4 Each of the parties agrees to execute and deliver such further
documents and to cooperate in such manner as may be necessary to implement and
give effect to the agreements contained herein.

     10.5 This Agreement shall be binding upon and shall inure to the benefit of
each party, its successors and permitted assigns.

     10.6 If any provision of this Agreement, or the application thereof, is
held to be invalid or unenforceable, the remainder of the Agreement shall
continue in full force and effect.

     10.7 The terms of this Agreement shall supersede the terms of any invoice,
confirmation, purchase order or other commercial document of the parties.

     10.8 The parties executing this Agreement warrant that they have the
requisite authority to do so.

     10.9 No waiver by either party of any condition, or of any breach of any
term, covenant, representation or warranty contained in this Agreement, in any
one or more instances, shall be deemed to be construed as a further breach or a
waiver of any other condition or of any breach of any other term, covenant,
representation or warranty.

     10.10 This Agreement sets forth the entire agreement and understanding
between the parties hereto respecting the subject matter hereof, and supersedes
all prior oral discussions and writing between the parties. No modifications,
extension or waiver of this Agreement or any provision thereof shall be binding
unless agreed to in writing by the parties.

     10.11 This Agreement shall inure to the benefit of and be binding upon the
parties and their agents, successors and permitted assigns.

     10.12 For the purpose of all provisions of this Agreement requiring the
giving of notice by either party to the other, notice shall be deemed to be
given when mailed by registered mail, postage prepaid, and sent to the addresses
given below for Signet and Senetek. The notices to Signet should be sent to the
attention of:

     Ronald J. Casciato, President
     Signet Laboratories
     180 Rustcraft Road
     Dedham, Massachusetts 02026

     The notices to Senetek should be sent to the attention of:

     Frank Massino, President
     Senetek PLC
     620 Airpark Road
     Napa, California 94558

                                       7

<PAGE>

                  IN WITNESS WHEREOF, the respective parties hereto have
executed this Agreement by their fully authorized officers on the date appearing
below their signatures.

                                     Signet Laboratories, Inc.

Date: September 29, 2000             By: /s/ Ronald J. Casciato
      ---------------------              -----------------------------
                                         Ronald J. Casciato, President

                                     Senetek PLC

Date:                                By: /s/ Frank Massino
      ---------------------              -----------------------------
                                         Frank Massino, President

                                       8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00036-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00036-of-00352.parquet"}]]